Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04713514
Title OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (TEDOVA)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors ARCAGY/ GINECO GROUP
Indications

ovary epithelial cancer

Therapies

OSE 2101 + Pembrolizumab

OSE 2101

Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.